Median survival follow-up was 384 years ( IQR 360-424 ) , and 3-year overall survival was 93 % ( 95 % CI 87-96 ) for lapatinib , 90 % ( 84-94 ) for trastuzumab , and 95 % ( 90-98 ) for combination therapy .